GLPG:NSD-Galapagos NV (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 204.65

Change

+4.45 (+2.22)%

Market Cap

USD 13.13B

Volume

0.15M

Average Target Price

USD 219.18 (+7.10%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjögren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-05-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-18.46 (-6.48%)

USD73.88B 49.39 37.03
REGN Regeneron Pharmaceuticals, Inc

-24.70 (-4.33%)

USD64.13B 28.64 21.76
SGEN Seattle Genetics, Inc

-4.04 (-2.59%)

USD26.26B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

+1.30 (+1.28%)

USD22.70B 9.81 8.43
INCY Incyte Corporation

-0.69 (-0.69%)

USD21.60B 47.64 35.20
MRNA Moderna, Inc

-11.29 (-16.36%)

USD21.42B N/A N/A
GMAB Genmab A/S

+1.22 (+4.16%)

USD19.59B 52.40 5.57
BMRN BioMarin Pharmaceutical Inc

+6.23 (+6.39%)

USD17.63B 154.78 92.86
ALNY Alnylam Pharmaceuticals, Inc

-4.09 (-2.91%)

USD16.13B N/A N/A
BGNE BeiGene, Ltd

+4.78 (+3.00%)

USD12.41B N/A N/A

ETFs Containing GLPG

Symbol Name Weight Mer Price(Change) Market Cap
EWK iShares MSCI Belgium Capp.. 6.84 % 0.49 %

+0.89 (+6.06%)

USD0.03B
AADR AdvisorShares Dorsey Wrig.. 6.22 % 1.10 %

+1.25 (+2.65%)

USD0.07B
FEUD:LSE First Trust Eurozone Alph.. 1.86 % 0.00 %

+76.00 (+3.14%)

USD0.16B
DJMC:LSE iShares EURO STOXX Mid UC.. 1.62 % 0.40 %

+172.00 (+3.83%)

USD0.29B
IQQM:F iShares EURO STOXX Mid UC.. 1.62 % 0.40 %

+1.34 (+2.63%)

USD0.29B
IQQM:XETRA iShares EURO STOXX Mid UC.. 1.62 % 0.40 %

+1.17 (+2.29%)

USD0.29B
2B78:XETRA iShares Healthcare Innova.. 1.48 % 0.40 %

-0.12 (-1.72%)

USD0.71B
DRDR:LSE iShares Healthcare Innova.. 1.45 % 0.40 %

+1.13 (+0.19%)

USD0.47B
HEAL:LSE iShares Healthcare Innova.. 1.45 % 0.40 %

+0.11 (+1.50%)

USD0.51B
JPIN JPMorgan Diversified Retu.. 0.48 % 0.37 %

+1.41 (+3.02%)

USD0.92B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.05% 48% F 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.05% 48% F 68% D+
Trailing 12 Months  
Capital Gain 71.48% 78% C+ 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 71.48% 78% C+ 90% A-
Trailing 5 Years  
Capital Gain 310.04% 93% A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 310.04% 93% A 94% A
Average Annual (5 Year Horizon)  
Capital Gain 41.99% 85% B 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 41.99% 84% B 91% A-
Risk Return Profile  
Volatility (Standard Deviation) 37.24% 61% D- 35% F
Risk Adjusted Return 112.77% 100% A+ 94% A
Market Capitalization 13.13B 98% A+ 95% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 70.13 12% F 15% F
Price/Book Ratio 4.16 52% F 28% F
Price / Cash Flow Ratio 4.09 9% F 46% F
EV/EBITDA 37.04 11% F 15% F
Management Effectiveness  
Return on Equity 7.37% 95% A 67% D+
Return on Invested Capital 18.10% 93% A 91% A-
Return on Assets 6.41% 96% A 89% B+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 5.43 41% F 24% F
Short Percent N/A N/A N/A N/A N/A
Beta 1.19 66% D 45% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.